Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | beta-amyloid |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6552H10158N1730O2090S52 |
Molar mass | 148272.48 g·mol−1 |
(what is this?) (verify) |
Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease. [1] [2]
Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial. [3]